Two-year follow-up results from an ongoing study on the safety and effectiveness of elexacaftor/tezacaftor/ivacaftor when used in real-world settings by people with cystic fibrosis
New drug for cystic fibrosis does not significantly interfere with another drug that prevents organ rejection
Infant with cystic fibrosis has normal pancreas function and was missed by newborn screening after mom stayed on CFTR modulator therapy during pregnancy.
A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous
